Holen Sie sich die Stockscreener-App
54.03
0.11%
-0.06
Handel nachbörslich:
54.03
Schlusskurs vom Vortag:
$54.09
Offen:
$54.02
24-Stunden-Volumen:
1.89M
Relative Volume:
0.91
Marktkapitalisierung:
$4.32B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-269.44M
KGV:
-14.41
EPS:
-3.75
Netto-Cashflow:
$-262.63M
1W Leistung:
+0.06%
1M Leistung:
+17.20%
6M Leistung:
+20.41%
1J Leistung:
+68.58%
1-Tages-Spanne:
$53.99
$54.10
1-Wochen-Bereich:
$53.84
$54.31
52-Wochen-Spanne:
$21.34
$58.40
Akero Therapeutics Inc Stock (AKRO) Company Profile
Firmenname
Akero Therapeutics Inc
Sektor
Branche
Telefon
650-487-6488
Adresse
601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO, CA
Vergleichen Sie AKRO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AKRO
Akero Therapeutics Inc
|
54.03 | 4.34B | 0 | -269.44M | -262.63M | -3.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.67 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
628.00 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
423.47 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
831.48 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.77 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
Akero Therapeutics Inc Stock (AKRO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-04 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-08-04 | Eingeleitet | TD Cowen | Buy |
| 2025-01-30 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-01-27 | Bestätigt | H.C. Wainwright | Buy |
| 2024-11-18 | Eingeleitet | Citigroup | Buy |
| 2024-04-22 | Fortgesetzt | BofA Securities | Neutral |
| 2023-09-19 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-08-28 | Eingeleitet | UBS | Buy |
| 2023-01-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-09-14 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2021-10-19 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-10 | Eingeleitet | BofA Securities | Buy |
| 2021-02-26 | Eingeleitet | Guggenheim | Buy |
| 2020-09-10 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-07-20 | Bestätigt | H.C. Wainwright | Buy |
| 2020-07-07 | Eingeleitet | Chardan Capital Markets | Buy |
| 2020-07-01 | Bestätigt | H.C. Wainwright | Buy |
| 2020-03-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-02-10 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-07-15 | Eingeleitet | Evercore ISI | Outperform |
| 2019-07-15 | Eingeleitet | JP Morgan | Overweight |
| 2019-07-15 | Eingeleitet | Jefferies | Buy |
| 2019-07-15 | Eingeleitet | ROTH Capital | Buy |
Alle ansehen
Akero Therapeutics Inc Aktie (AKRO) Neueste Nachrichten
Why (AKRO) Price Action Is Critical for Tactical Trading - news.stocktradersdaily.com
Will Akero Therapeutics Inc. stock reach Wall Street targetsJuly 2025 Weekly Recap & Capital Efficiency Focused Strategies - newser.com
Can volume confirm reversal in Akero Therapeutics Inc.Weekly Trend Summary & Safe Capital Investment Plans - newser.com
How high can Akero Therapeutics Inc. stock goEarnings Trend Report & Daily Growth Stock Tips - newser.com
Can Akero Therapeutics Inc. (0K4) stock deliver strong annual returnsPortfolio Return Report & AI Powered Market Entry Ideas - newser.com
Heatmap analysis for Akero Therapeutics Inc. and competitorsJuly 2025 Patterns & Community Supported Trade Ideas - newser.com
Is Akero Therapeutics Inc. (0K4) stock a contrarian opportunity - newser.com
Can Akero Therapeutics Inc. (0K4) stock beat analyst consensusJuly 2025 Movers & Reliable Entry Point Alerts - newser.com
Will Akero Therapeutics Inc. (0K4) stock rise with strong economyTrade Analysis Report & Real-Time Volume Surge Alerts - newser.com
Is Akero Therapeutics Inc. stock a buy before product launchesWeekly Trade Review & Weekly Watchlist for Hot Stocks - newser.com
Will Akero Therapeutics Inc. stock gain from lower inflationTrade Risk Assessment & Precise Entry and Exit Recommendations - newser.com
How rising interest rates impact Akero Therapeutics Inc. stockCEO Change & AI Driven Price Predictions - newser.com
Can Akero Therapeutics Inc. (0K4) stock surprise with quarterly resultsWeekly Loss Report & Community Driven Trade Alerts - newser.com
Will Akero Therapeutics Inc. outperform the marketGap Down & Comprehensive Market Scan Insights - newser.com
Why Akero Therapeutics Stock Trounced the Market on Thursday - AOL.com
Using RSI to spot recovery in Akero Therapeutics Inc.Gap Up & Expert Curated Trade Setups - newser.com
Chart based analysis of Akero Therapeutics Inc. trendsWeekly Market Outlook & Entry Point Confirmation Signals - newser.com
Is Akero Therapeutics Inc. stock a top pick in earnings seasonPortfolio Risk Summary & Technical Entry and Exit Alerts - newser.com
Jennison Associates LLC Grows Stock Position in Akero Therapeutics, Inc. $AKRO - MarketBeat
Y Intercept Hong Kong Ltd Takes Position in Akero Therapeutics, Inc. $AKRO - MarketBeat
Akero Therapeutics, Inc. (NASDAQ:AKRO) Short Interest Update - MarketBeat
Fatty liver disease companies' multibillion-dollar deals mean fatter walletsSan Francisco Business Times - The Business Journals
Is Akero Therapeutics Inc. trending in predictive chart modelsJuly 2025 Levels & Weekly High Return Opportunities - newser.com
Emerald Mutual Fund Advisers Trust Has $7.27 Million Stock Position in Akero Therapeutics, Inc. $AKRO - MarketBeat
Is Akero Therapeutics Inc. (0K4) stock included in top ETFsJuly 2025 Trends & Stepwise Trade Signal Guides - newser.com
Why Akero Therapeutics Inc. stock is recommended by analystsTrade Analysis Report & Free Low Drawdown Momentum Trade Ideas - newser.com
Altimmune: Competitor Buyouts Plus Regulatory And Clinical Progress (NASDAQ:ALT) - Seeking Alpha
Akero Stock Hits Over 18-Month High On MASH Trial Data: Citi Lauds ‘Best-Case Scenario,’ Retail Exuberant - MSN
Finanzdaten der Akero Therapeutics Inc-Aktie (AKRO)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):